Goldman Sachs Resumes Sara Lee (SLE) at Buy, Confusion Create Opportunity
Tweet Send to a FriendGet Alerts SLE Hot Sheet
Price: $18.50 --0%
Rating Summary:
5 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
5 Buy, 2 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade SLE Now!
Goldman Sachs resumed coverage on Sara Lee (NYSE: SLE) with a Buy rating and $19 price target.
The firm said their is confusion and cost concerns after the company's plans to split in two, which creates a buying opportunity.
The firm sees 34% total return potential based on "(a) our sum-of-the parts valuation, (b) its strategic value as an M&A candidate and (c) the distribution of cash to shareholders in the form of a $3 special dividend."
For more ratings news on Sara Lee click here and for the rating history of Sara Lee click here.
Shares of Sara Lee closed at $16.76 yesterday, with a 52 week range of $12.83-$20.26.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said their is confusion and cost concerns after the company's plans to split in two, which creates a buying opportunity.
The firm sees 34% total return potential based on "(a) our sum-of-the parts valuation, (b) its strategic value as an M&A candidate and (c) the distribution of cash to shareholders in the form of a $3 special dividend."
For more ratings news on Sara Lee click here and for the rating history of Sara Lee click here.
Shares of Sara Lee closed at $16.76 yesterday, with a 52 week range of $12.83-$20.26.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Deutsche Bank Starts Alnylam Pharmaceuticals (ALNY) at Buy
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage, Special DividendsRelated Entities
DividendLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

